High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence

Movement Disorders

Volumn 22, Issue 7, 2007, Pages 969-973

  Stefanova, Nadia ^a   Köllensperger, Martin ^a   Hainzer, Monika ^a   Cenci, Angela ^b   Poewe, Werner ^a   Wenning, Gregor Karl ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b LUND UNIVERSITY   (Sweden)

Author keywords

synuclein; Glial cytoplasmic inclusions; Levodopa; Multiple system atrophy; Neurodegeneration; Transgenic mouse

Indexed keywords

ALPHA SYNUCLEIN; BENSERAZIDE; LEVODOPA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; LOW DRUG DOSE; MOUSE; NERVE CELL; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OLIGODENDROGLIA; OPEN FIELD BEHAVIOR; OXIDATIVE STRESS; PRIORITY JOURNAL; PURKINJE CELL; RISK FACTOR; SHY DRAGER SYNDROME; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMAL DISEASES; ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; LEVODOPA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; MULTIPLE SYSTEM ATROPHY; NERVE TISSUE PROTEINS;

EID: 34347215900     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21468     Document Type: Article

References (30)

1. Fahn S. Is levodopa toxic? Neurology 1996;47:S184-S195.
2. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19:997-1005.
3. Muller T, Hefter H, Hueber R, Jost WH, Leenders KL, Odin P, Schwarz J. Is levodopa toxic? J Neurol 2004;251 (Suppl 6):VI/44-VI/46.
4. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3:93-103.
5. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117 (Part 4):835-845.
6. Albanese A, Colosimo C, Bentivoglio AR, et al. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry 1995;59:144-151.
7. Parati EA, Fetoni V, Geminiani GC, et al. Response to L-DOPA in multiple system atrophy. Clin Neuropharmacol 1993;16:139-144.
8. Colosimo C, Tiple D, Wenning GK. Management of multiple system atrophy: state of the art. J Neural Transm 2005;112:1695-1704.
9. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992;55:1009-1013.
10. Colosimo C, Albanese A, Hughes AJ, de Bruin VM, Lees AJ. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 1995;52:294-298.
11. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-166.
12. Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990;13:553-558.
13. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998; 8:359-362.
14. Scherfler C, Puschban Z, Ghorayeb I, et al. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience 2000;99: 43-54.
15. Stefanova N, Puschban Z, Fernagut PO, et al. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta Neuropathol (Berl) 2003;106:157-166.
16. Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. Animal models of multiple system atrophy. Trends Neurosci 2005;28:501-506.
17. Stefanova N, Reindl M, Neumann M, et al. Oxidative stress in transgenic mice with oligodendroglial α-synuclein overexpressibn replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005;166:869-876.
18. Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of α-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3:583-588.
19. Burke WJ, Joh TH. Effect of dopamine on tyrosine hydroxylase in cultured rat adrenal medulla. Biochem Pharmacol 1988;37:1391-1397.
20. Mena MA, Pardo B, Casarejos MJ, Fahn S, Garcia dY. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7:23-31.
21. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993;61: 1470-1478.
22. Basma AN, Morris EJ, Nicklas WJ, Geller HM. L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 1995;64:825-832.
23. Lai CT, Yu PH. Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol 1997;53: 363-372.
24. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model 5 of oxidative stress. J Pharmacol Exp Ther 2003;304:792-800.
25. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43:990-993.
26. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2, or D-3 receptor in the striatum of normal monkeys: an autoradiographic study. J Neural Transm 2001;108:925-941.
27. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
28. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-575.
29. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252 (Suppl 4):IV37-IV42.
30. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47:S161-S170.